Novartis sticks to 2011 goals as sales jump

Swiss drugmaker Novartis AG stuck to its 2011 outlook after posting better-than-expected first-quarter sales as demand for its products remained robust. Novartis, the maker of high blood pressure drug Diovan, reported first-quarter core earnings per share of $1.41, in line with the average analyst forecast in a Reuters poll of $1.40.